Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Smoking damages the blood vessels in the eyes, which over time increases the risk for several complications, including ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular degeneration.